CG Oncology, Inc. (CGON)
(Delayed Data from NSDQ)
$36.49 USD
+1.12 (3.17%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $36.48 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
CG Oncology, Inc. [CGON]
Reports for Purchase
Showing records 1 - 5 ( 5 total )
Company: CG Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Full CORE-001 Results at ASCO Delivers Another Win for Cretostimogene
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: CG Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Update From Creto + Pembro During ASCO?24 Can Further Cement Creto?s Place in NMIBC
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: CG Oncology, Inc.
Industry: Medical - Biomedical and Genetics
AUA ?24 Hosted a True "Ali vs Frazier" Fight in NMIBC with Cretostimogene Against TAR-200
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: CG Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Cretostimogene Looks to Impress with 12-Month CR Data from Pivotal BOND-003 Study During AUA ?24
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: CG Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Cretostimogene?s Regime Aims to Transform the NMIBC Scene; Initiating Coverage With a Buy Rating and $75 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
|